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ABSTRACT 
Objectives: Amodiaquine (AQ) is a 4-aminoquinoline antimalarial drug that is rapidly and extensively metabolized mainly by CYP2C8 enzyme to N-
desethylamodiaquine (DEAQ). Co-trimoxazole (CTZ) is a combination (sulfamethoxazole and trimethoprim) antimicrobial agent with the 
trimethoprim component being a potent inhibitor of CYP2C8. AQ and CTZ are likely to be co-administered in the treatment of patients with malaria 
and susceptible bacterial infections. This study evaluates the effect of CTZ co-administration on the pharmacokinetics of AQ.  
Methods: In an open, two-way crossover study, 16 healthy volunteers were randomized to receive 600 mg single oral dose of AQ with or without 
the eleventh dose of CTZ (960 mg every 12 h for 7 days.) Blood samples were collected at pre-determined time intervals and analyzed for AQ and its 
major metabolite, DEAQ using a validated HPLC method.  
Results: Co-administration of AQ and CTZ resulted in significant increases in the total area under the concentration–time curve (AUCT), maximum 
plasma concentration (Cmax) and terminal elimination half-life (T½) of AQ compared with values with AQ dosing alone (AUCT:  234.36±57.21 vs 
366.42±62.48 h ng/ml; Cmax: 24.86±7.28 vs 40.28±11.15 ng/ml; T½: 6.49±3.56 vs 9.24±2.97 h), while the oral plasma clearance markedly decreased 
(3862.66±756.38 vs 2654.28±650.12 L/h). Co-administration also led to a pronounced decrease in the ratio of AUC(metabolite)/AUC (unchanged drug) and 
highly significant decreases in Cmax
Conclusion: Study evaluated for the first time the effect of CTZ co-administration on the pharmacokinetics of AQ in healthy adult volunteers. CTZ 
significantly increased AQ exposure and decreased plasma levels of the active metabolite DEAQ.  
 and AUC of the metabolite.  
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INTRODUCTION 
Cytochrome P450 (CYP) enzymes represent a family of proteins that 
contribute predominantly to the metabolism of drugs and other 
xenobiotics. Alteration in the activity of these enzymes in vivo 
represents the major underlying mechanism behind pharmacokinetic 
drug-drug interactions [1]. In humans, some CYP enzymes have been 
designated as more predominant in the metabolism of drugs than 
others. These include CYP1A2, 2C9, 2C19, 2D6, 2E1 and 3A4. These six 
enzymes have been studied extensively with regard to their role in 
drug metabolic clearance as well as drug-drug interactions [2].  
However; other investigations have uncovered roles for other CYP 
enzymes, such as CYP2C8, in the metabolism of some drugs. Thus, 
CYP2C8 can also be the target of drug-drug interactions for those 
drugs in which it plays a predominant role in the clearance [3]. Drug 
interactions that arise by inhibition of CYP2C8 have been described, 
including interactions between cerivastatin and gemfibrozil [4], 
repaglinide, and gemfibrozil [5], and repaglinide and trimethoprim [6]. 
Amodiaquine (AQ), [4-(7-chloro-4-quinolylamino)-2-(diethyl 
aminomethyl) phenol dihydrochloride] is a 4-aminoquinoline 
antimalarial which act by inhibiting the degradation of hemoglobin 
in the food vacuole of plasmodium parasite [7]. After oral 
administration, AQ undergoes rapid and extensive hepatic 
metabolism by N-dealkylation to the active metabolite, N-desethyl-
amodiaquine (DEAQ) with CYP2C8 as the main CYP isoform 
responsible for the biotransformation [8, 9], (fig. 1). It has been 
widely used for treatment of malaria over the past 50 years [9]. AQ 
is more active than chloroquine (also a 4-aminoquinoline) against 
Plasmodium falciparum parasites which are moderately chloroquine 
resistant [9, 10]. Due to widespread chloroquine resistance, AQ is 
being considered as a replacement for chloroquine as a first line 
drug in Africa but severe side effects such as agranulocytosis and 
















Fig. 1: AQ and its main metabolite DEAQ 
 
Subsequent to chloroquine discontinuation over a decade ago, the 
guidelines to treat falciparum malaria suggest combination 
therapies, preferentially with an artemisinin derivative. One of the 
recommended partner drugs is AQ, a pro-drug that relies on its 
active metabolite DEAQ, and is still effective in areas of Africa [12, 
13]. Following rapid absorption and extensive metabolism of AQ 
after oral administration, very little of the parent drug is detected in 
the plasma [9, 12]. The main metabolite of AQ is DEAQ with other 
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minor metabolites being 2-hydroxyl-DEAQ and N-bisDEAQ [9, 13]. 
Although the formation of DEAQ is rapid, its elimination is very slow 
with a terminal half-life of over 100 hours. Both AQ and DEAQ 
possess antimalarial activity with AQ being 3 times more potent 
than DEAQ [9, 13]. Because AQ is rapidly cleared and the formed 
DEAQ attains high plasma concentrations for a long time, AQ is 
considered a pro drug, which is bioactivated to DEAQ [9, 13]. 
Co-trimoxazole, [(CTZ) a combination of sulfamethoxazole and 
trimethoprim] is an inhibitor of bacterial purine biosynthesis and is 
commonly used to treat HIV-associated Pneumocystis 
jiroveci infections [14]. The standard treatment dose of CTZ (960 mg 
12 hourly) has been reported to interfere with the elimination of 
several drugs by various mechanisms. Competitive inhibition with 
trimethoprim for the human organic cation transporter (hOCT) has 
been implicated in the decreased renal tubular secretion of the 
nucleotide reverse transcriptase inhibitors (NRTI) zidovudine and 
lamivudine [15,16],whereas a reversible increase in serum creatinine 
has been reported during concomitant treatment with cyclosporin and 
CTZ in renal transplant patients [17]. In vitro data suggest that at 
clinical doses, sulfamethoxazole and trimethoprim selectively inhibit 
the CYP isoenzymes CYP2C9 and 2C8 respectively and lose their 
specificity at higher concentrations (500 μM and 100 μM, 
respectively), inhibiting several CYP isoforms, including CYP3A4 [18]. 
Since AQ is a substrate for CYP2C8, and trimethoprim, one of the 
components of CTZ is a potent inhibitor of this isozyme, there is a 
potential for a pharmacokinetic interaction between these two 
agents. However, the magnitude and clinical significance of such an 
interaction can only be evaluated through studies. Patients receiving 
treatment with CTZ for susceptible infections may require 
concomitant treatment with AQ for malaria infection. There is very 
sparse information on interaction between CTZ and antimalarial 
drugs, and there is no published data on pharmacokinetic 
interaction between CTZ and AQ. The aim of the present study 
therefore, was to determine the effect of steady state CTZ on the 
pharmacokinetics of AQ in healthy volunteers.  
MATERIALS AND METHODS 
Chemicals and reagents 
AQ dihydrochloride and DEAQ dihydrochloride were obtained from 
Parke-Davis, U. S. A., and quinidine from BDH Laboratory Supplies, 
Poole, England. AQ dihydrochloride tablets (Parke-Davis, U. S. A.) 
were purchased from a retail pharmacy in Nigeria. HPLC grade 
acetonitrile and methanol, and analytical grade diethylether, 
perchloric acid, sodium hydroxide and hydrochloric acid were 
purchased from Sigma (Sigma-Aldrich chemical company, Germany).  
Instruments and chromatographic conditions 
The High Performance Liquid Chromatography (HPLC) system consisted 
of Agilent fitted automatic injector system fitted with a variable UV 
detector. The stationary phase was a reversed-phase C18 column 
[Zobrax Eclipse C18-3.5 µm (200 x 4.6 mm I.D.)]. The solvent system for 
HPLC consisted of acetonitrile: 0.02 M potassium dihydrogen phosphate 
(10:90). The pH of the mobile phase was adjusted to 4.0 with 
orthophosphoric acid. The mobile phase was pumped through the 
column at a flow rate of 1.0 mL/min. The experiments were performed 
at ambient temperature. The method was a slight modification of Gitau 
et al., (2004) [19]. Whirl mixer (Fissions), precisions pipettes (MLA), 
table centrifuge (Gallenkamp) and digital sonicator (Gallenkamp) were 
used for the extraction procedure. 
Analytical procedure 
To 1 mL of plasma placed in a 15-mL screw capped extraction tube, 
were added 20 µl of 500 µg/ml quinidine solutions (internal 
standard) and 2 mL of acetonitrile before mixing for about 15 
seconds, followed by mechanical tumbling for 15 min. After 
centrifuging for 10 min at 3000 g, the liquid phase was transferred 
to a clean tube, to which was added 2 mL of ammonia. The mixture 
was then extracted by mechanical tumbling for 15 min, with 2 x 5 
mL of diethyl ether. After centrifugation and separation, the 
combined organic phases were evaporated to dryness and the 
residue was reconstituted in 100 µl of methanol while a 50 µl aliquot 
was injected onto the HPLC column. Calibration curve based on peak 
area ratio was prepared by spiking drug-free plasma with standard 
solutions of AQ and DEAQ to give concentration ranges of 2–30 
ng/ml and 20–300 ng/ml respectively. The samples were taken 
through the extraction procedure described above. 
Subjects 
Twelve males and four females adult Nigerians, aged between 30 and 
38 years and weighing between 64 and 75 kg took part in the study. 
They were all judged healthy by a physician on the basis of medical 
history, clinical examination, biochemical, and hematological 
screening prior to entry into the study. Subjects were excluded from 
participating if they met one of the following criteria: pregnancy, 
breast feeding, history of hypersensitivity reactions to AQ or similar 
agents (Chloroquine, quinidine, quinolones), use of any medications 
that could potentially interact with the study drug, any liver function 
test more than three times the upper limit of normal, or evidence by 
history or physical examination of gastrointestinal, psychiatric, 
cardiovascular or neurological disorders. All participants gave written 
informed consent, and approval was obtained from the Research 
Ethics Board and safety Committee of the College of Health Sciences, 
Osun State University, Osogbo. 
Study design, drug administration and sample collection  
The study was an open-label, crossover pharmacokinetic study. A 
single oral dose of 600 mg AQ dihydrochloride tablets was given to 
each of the sixteen volunteers with and without the eleventh dose of 
960 mg CTZ (given 12 hourly) in a crossover design after an 
overnight fast. 5 ml blood samples were withdrawn by venipuncture 
from the forearm of each subject prior to and at 0.08, 0.25, 0.5, 1.5, 3, 
5, 24, 48 and 96 hours after drug administration into heparinized 
tubes. They were immediately centrifuged (3000 g at 20 oC for 10 
min) to separate plasma. The plasma aliquots were stored at-20 oC 
until analyzed. The plasma samples were analyzed for AQ and DEAQ 
to obtain their baseline pharmacokinetics and then to evaluate the 
effect of CTZ on the pharmacokinetics of AQ.  
Pharmacokinetic evaluation 
The pharmacokinetic (PK) parameters for AQ and DEAQ were calculated 
with the computer program WinNonLin (version 1.5). The data were 
analyzed using non-compartmental analysis. The parameters that could 
be established were as follows: time point of maximum observed 
concentration in plasma (Tmax); concentration in plasma corresponding 
to Tmax (Cmax); terminal half-life (T1/2); area under the plasma 
concentration versus time (C-t) curve (AUCT). The terminal half-life was 
calculated from the terminal elimination rate constant: k. This rate 
constant was calculated by means of linear regression of the final part of 
the ln C-t curve. The final half-life could be calculated by T1/2 = ln (2)/k = 
0.693/k. For the calculation of the elimination rate constant, we used the 
three final concentrations of the C-t curve (24, 48, and 96 h). The AUCT
All subjects tolerated the 600 mg single oral dose of AQ. The most 
frequently reported adverse event was mild nausea (all subjects). 
Mild abdominal pain occurred in a further five subjects. There were 
no serious adverse events during the study and no withdrawal due 
to adverse events or for any other reason. The extraction procedure 
employed in this study produced clean and clear supernatants from 
plasma as there was no interference from endogenous compounds. 
AQ was well resolved from its major metabolite and from the 
internal standard. The limit of quantification for AQ and DEAQ were 
0.5 ng/ml and 10 ng/ml respectively. The pharmacokinetic 
parameters obtained following administration of AQ alone or with 
CTZ are presented in table 1. 
 
was calculated by the logarithmic trapezoidal rule.  
Statistical evaluation was performed with the statistical program 
SPSS 7.0. Direct comparisons of the raw data were performed using 
the two-tailed paired t test. The Wilcoxon matched pairs signed 
ranked test was used to evaluate the difference between any pair of 
data, i.e. effects of CTZ on the pharmacokinetics of AQ or on DEAQ 
disposition. Results were recorded as mean±SD. In all, a value of 
P<0.05 was considered statistically significant. 
RESULTS 
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Table 1: Effect of co-administration of CTZ on the pharmacokinetic parameters of AQ and DEAQ 
Parameters AQ alone AQ with CTZ Significance 
AQ    
Cmax 24.86±7.28  (ng/ml) 40.28±11.15 P<0.05 
Tmax 2.80±1.71  (h) 3.86±2.14 P<0.05 
AUCT 234.36±57.21 (h. ng/ml) 366.42±62.48 P<0.05 
T1/2 6.49±3.56 (h) 9.24±2.97 P<0.05 
C24h 5.23±1.25  (ng/ml) 6.19±1.42 P<0.05 
CL/F (L/h) 3862.66±756.38 2654.28±650.12 P<0.05 
Vd 60275.48±2125.25 /F (L) 64865.32±2324.27 P<0.05 
DEAQ    
Cmax 560.28±102.16  (ng/ml) 420.16±98.27 P<0.05 
Tmax 4.62±1.54  (h) 4.54±2.16 P>0.05 
T1/2 189.23±16.24  (h) 126.52±13.37 P<0.05 
AUC0-96 18560.26±1420.36  (h. ng/ml) 16218.76±1280.44 P<0.05 
C96h 85.46±16.28  (ng/ml) 70.24±14.19 P<0.05 
MR 79.19±3.56 44.26±2.68 P<0.05 
Cmax:  peak plasma concentration, Tmax:  time to Cmax, AUC: area under the concentration–time curve, T1/2: terminal half-life, CL/F: apparent oral 
clearace, Vd
 
/F: apparent volume of distribution, MR: metabolic ratio 
Co-administration of CTZ was associated with marked increases 
(P<0.05) in the Cmax and AUCT of AQ compared with the values 
obtained following administration of the antimalarial alone (table 1). 
The results show that the Cmax, Tmax, AUCT and elimination T1/2 of 
AQ increased by 62% [95% confidence interval (CI) 55, 70], 37% 
[95% CI 35, 42], 56% [95% CI 60, 65] and 42% [95% CI 38, 46], 
respectively, in the presence of CTZ. Also, the oral plasma clearance 
(CL/F) of AQ was highly reduced with CTZ co-administration by 
about 31% [95% CI 28, 34]. The pharmacokinetic parameters of 
DEAQ following administration of AQ, with and without CTZ, are also 
shown in table 1. The Cmax, T1/2 and AUC0–96h of the metabolite were 
significantly diminished in the presence of CTZ (P<0.05). The Cmax 
reduced by 25% [95% CI 21, 28], T1/2 reduced by 33% [95% CI 30, 
35], while AUC0–96h 
  






Fig. 2: Plasma concentration–time profile of (A) AQ and (B) 
DEAQ following administration of 600 mg AQ to 16 healthy 
volunteers with or without CTZ co-administration 
Co-administration of CTZ also resulted in a pronounced decrease in 
the ratio of the AUC of AQ metabolite to that of unchanged drug (i.e. 
metabolic ratio, MR) by about 44% [95% CI 40, 48]. There was no 
significant change (P>0.05) in the Tmax
Fig. 2 shows the mean±SD plasma concentration vs. time profiles of 
AQ and DEAQ following oral administration of single doses of 600 
mg of AQ tablets alone, and with CTZ co-administration, to each of 
16 volunteers. 
 of the metabolite. There were 
no significant differences between the treatment groups regarding 
adverse events, vital signs, and laboratory tests, (data not shown). 
DISCUSSION 
This study was performed to evaluate the effect of CTZ co-
administration on the pharmacokinetics of AQ, a 4-aminoquinoline 
antimalarial drug. Previous reports have shown that AQ is well 
absorbed from the gastrointestinal tract with a Tmax in the range of 
2.7–3.0 h. Its elimination half-life is approximately 5 h and is rapidly 
cleared by extensive metabolism followed by excretion of 
metabolites in the urine [20]. The results from the present study 
indicate that the pharmacokinetic parameters obtained for AQ when 
administered alone, such as Tmax, elimination T1/2, CL/F, and AUCT are 
generally in agreement with the values obtained in other single dose 
pharmacokinetic studies [20-22]. With CTZ co-administration, the 
observed marked increase in the Tmax
Since AQ is a substrate for P-glycoprotein [24],it is possible for its 
absorption to be prolonged by P-glycoprotein up-regulation caused 
by CTZ. This speculation is based on reports indicating that drug-
induced increase in P-glycoprotein expression can result in 
prolongation of T
 of AQ (table 1) which is 
indicative of a slower rate or prolongation of absorption of the 
antimalarial may be attributed to the modulation of intestinal P-
glycoprotein by CTZ. It has been demonstrated that CTZ is not a P-
glycoprotein substrate but can slightly induce P-glycoprotein 
functionality and expression probably through induced cell stress [23]. 
max of a co-administered drug. For example, the 
Tmax of levofloxacin was prolonged by 50% following efavirenz co-
administration and this was ascribed to up-regulation of P-
glycoprotein induced by efavirenz [25]. Moreover, in our previous 
study, the Tmax of proguanil was prolonged significantly following 
concomitant administration with efavirenz and this was ascribed to 
up-regulation of P-glycoprotein induced by efavirenz [26]. The total 
systemic exposure (AUCT) of AQ was substantially increased (mean 
of about 80%) in the presence of CTZ (table 1) and this is quite 
evident in the significant difference in the plasma concentration 
profiles of AQ with or without CTZ administration (fig. 2A). The 
increased systemic drug exposure coupled with the markedly 
diminished oral drug clearance (CL/F) and significantly prolonged 
elimination T1/2 of AQ suggests a systemic inhibition of metabolism 
of the drug by CTZ. This assertion is buttressed by the observation of 
an evident marked reduction in plasma levels of the major 
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metabolite (DEAQ) (fig. 2B), which is reflected in significant decreases in 
the Cmax
In our previous study looking at AQ pharmacokinetics following co-
administration with 600 mg efavirenz once daily, efavirenz 
significantly increased AQ C
 and AUC of the metabolite. Previous studies have shown that 
both CYP2C8 and CYP3A4 contribute to the metabolism of AQ but the 
former is the major contributor to the biotransformation [27, 28]. Since 
trimethoprim, a component of CTZ has been demonstrated as an 
inhibitor of CYP2C8 as well as a mixed inducer/inhibitor of CYP3A4 [18], 
the increase in plasma levels of AQ following co-administration with CTZ 
is most likely due to the inhibition of CYP2C8 and probably a 
contribution from CYP3A4 inhibition.  
max and AUCT 
This study was carried out in healthy volunteers, and it is pertinent 
to note that changes in AQ pharmacokinetics occur in patients with 
malaria. In malaria, there is an elevated level of α-1-acid 
glycoprotein that is proportional to the severity of the infection. The 
raised concentrations of this protein account for increased plasma 
protein binding of AQ with resultant increased plasma AQ levels in 
malaria [24]. Since the unbound fraction of AQ in plasma is lower in 
patients with malaria, the degree of interaction between the drug 
and CTZ in these patients might be different from that observed in 
healthy subjects. 
[29]. Table 1 shows a 
pronounced decrease (44%) in the ratio of AUC of metabolite to that 
of unchanged drug (MR). This further strengthens the point that a 
metabolic interaction occurs between AQ and CTZ, and that CTZ 
inhibits the metabolism of AQ. The increased plasma levels of AQ as 
the result of inhibition of its metabolism by the co-administered CTZ 
may increase the risk of hepatotoxicity and agranulocytosis adverse 
events of AQ. After oral administration, AQ is rapidly absorbed from 
the gastrointestinal tract. In the liver, it undergoes rapid and 
extensive metabolism to DEAQ which concentrates in blood cells 
[11, 13]. AQ is three times more potent than DEAQ but the 
concentration of AQ in blood is quite low [11, 12]. Therefore, DEAQ 
is responsible for most of the observed antimalarial activity, and 
inhibition of AQ metabolism by co-administered CTZ, also decreases 
plasma level of DEAQ which may also lead to a decreased 
antimalarial protection. 
CONCLUSION 
This study evaluated for the first time the effect of CTZ co-
administration on the pharmacokinetics of AQ in healthy adult 
volunteers. CTZ significantly increased AQ exposure and decreased 
plasma levels of the main active metabolite, DEAQ. Consequently, 
the toxicity of AQ and antimalarial protection of DEAQ may be 
increased and decreased respectively when CTZ is co-administered 
with AQ. More studies are needed to further evaluate impact of this 
interaction and of CYP2C8 genetic polymorphisms on the clinical 
outcomes of treatment. 
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